These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33591615)

  • 1. Autologous intralesional platelet rich plasma improves melasma.
    Tuknayat A; Thami GP; Bhalla M; Sandhu JK
    Dermatol Ther; 2021 Mar; 34(2):e14881. PubMed ID: 33591615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-rich plasma treatment for melasma: A pilot study.
    Sirithanabadeekul P; Dannarongchai A; Suwanchinda A
    J Cosmet Dermatol; 2020 Jun; 19(6):1321-1327. PubMed ID: 31568636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma.
    Patil NK; Bubna AK
    Dermatol Ther; 2022 Jul; 35(7):e15534. PubMed ID: 35460158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study.
    Abd Elraouf IG; Obaid ZM; Fouda I
    Arch Dermatol Res; 2023 Aug; 315(6):1763-1770. PubMed ID: 36856856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of autologous platelet-rich-plasma versus its combination with intense pulsed light in treatment of melasma.
    Adel S; Serri A; Abd El-Raheem T
    Dermatol Ther; 2021 Jul; 34(4):e15008. PubMed ID: 34041826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-rich plasma is a useful therapeutic option in melasma.
    Hofny ERM; Abdel-Motaleb AA; Ghazally A; Ahmed AM; Hussein MRA
    J Dermatolog Treat; 2019 Jun; 30(4):396-401. PubMed ID: 30220226
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of autologous platelet rich plasma and hydroquinone 4% is more effective than hydroquinone alone in treatment of melasma: A split-face comparative study.
    Tekam PS; Belgaumkar VA
    Dermatol Ther; 2022 Nov; 35(11):e15761. PubMed ID: 36068674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of platelet-rich plasma efficacy in melasma.
    Acar A; Ozturk A; Sokmen N; Unal I; Ertam Sagduyu I
    J Cosmet Laser Ther; 2022 Jul; 24(1-5):36-39. PubMed ID: 35852165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of TGF-β protein in the lesional skins of melasma patients following treatment with platelet-rich plasma.
    Hofny ERM; Hussein MRA; Ghazally A; Ahmed AM; Abdel-Motaleb AA
    J Cosmet Laser Ther; 2019; 21(7-8):382-389. PubMed ID: 31554441
    [No Abstract]   [Full Text] [Related]  

  • 10. Intradermal Platelet-Rich Plasma for the Treatment of Melasma: A Clinical and Dermoscopic Evaluation in Dark Skin.
    Rout A; Mani S; Bala N
    J Cutan Aesthet Surg; 2023; 16(4):300-305. PubMed ID: 38314355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-rich plasma is a promising therapy for melasma.
    Tuknayat A; Bhalla M; Thami GP
    J Cosmet Dermatol; 2021 Aug; 20(8):2431-2436. PubMed ID: 34013618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Platelet-Rich Plasma Therapy as an Adjuvant in Treatment of Melasma.
    Bikash C; Sarkar R; Relhan V; Singh S
    Dermatol Surg; 2022 Apr; 48(4):429-434. PubMed ID: 35143442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical results of oral tranexamic acid and platelet rich plasma therapies in melasma treatment.
    Polat Y; Saraç G
    Dermatol Ther; 2022 Jul; 35(7):e15499. PubMed ID: 35395121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-Rich Plasma in Melasma-A Systematic Review.
    Sarkar R; Gupta M
    Dermatol Surg; 2022 Jan; 48(1):131-134. PubMed ID: 34904579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, dermoscopic, and histopathologic evaluation of vitamin C versus PRP, with microneedling in the treatment of mixed melasma: A split-face, comparative study.
    Abdel-Rahman AT; Abdel-Hakeem FG; Ragaie MH
    Dermatol Ther; 2022 Feb; 35(2):e15239. PubMed ID: 34851010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of melasma with platelet-rich plasma: A self-controlled clinical trial.
    González-Ojeda A; Cervantes-Guevara G; Chejfec-Ciociano JM; Cervantes-Cardona GA; Acevedo-Guzman D; Puebla-Mora AG; Cortés-Lares JA; Chávez-Tostado M; Álvarez-Villaseñor AS; Cervantes-Pérez E; Ramos-Álvarez MP; Pacheco-Vallejo LR; Barbosa-Camacho FJ; Fuentes-Orozco C
    Dermatol Ther; 2022 Sep; 35(9):e15703. PubMed ID: 35831241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Study of Growth Factor Concentrate Therapy for Treatment of Melasma.
    Sthalekar B; Agarwal M; Sharma V; Patil CY; Desai M
    Indian Dermatol Online J; 2021; 12(4):549-554. PubMed ID: 34430458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of efficacy of microneedling and mesoneedling in the treatment of epidermal melasma: A pilot trial.
    Farshi S; Mansouri P
    J Cosmet Dermatol; 2020 May; 19(5):1093-1098. PubMed ID: 32196865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma.
    Gamea MM; Kamal DA; Donia AA; Hegab DS
    J Dermatolog Treat; 2022 Mar; 33(2):798-804. PubMed ID: 32567984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability, Validity, and Sensitivity to Change Overtime of the Modified Melasma Area and Severity Index Score.
    Abou-Taleb DA; Ibrahim AK; Youssef EM; Moubasher AE
    Dermatol Surg; 2017 Feb; 43(2):210-217. PubMed ID: 27930379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.